Bile acid sequestration reduces plasma glucose levels in db/db mice by increasing its metabolic clearance rate

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Meissner, Maxi ^a   Herrema, Hilde ^a,b,c   van Dijk, Theo H ^a   Gerding, Albert ^a   Havinga, Rick ^a   Boer, Theo ^a   Müller, Michael ^b,c   Reijngoud, Dirk Jan ^a   Groen, Albert K ^a   Kuipers, Folkert ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; CARBON 13; COLESEVELAM; GLUCOKINASE; GLUCOSE; LONG CHAIN FATTY ACID; MESSENGER RNA; PARACETAMOL; BILE ACID; CARBON; CARNITINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; CONTROLLED STUDY; FAT CONTENT; FATTY ACID METABOLISM; FIBROBLAST GROWTH FACTOR 21 GENE; GENE; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN LIVER LEVEL; IN VIVO STUDY; LEAN BODY WEIGHT; LIVER PARENCHYMA; MALE; METABOLIC CLEARANCE RATE; MOUSE; NONHUMAN; SKELETAL MUSCLE; ANIMAL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; LIVER; METABOLISM; MOUSE MUTANT;

MURINAE; MUS;

ANIMALS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CARBON ISOTOPES; CARNITINE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; LIVER; METABOLIC CLEARANCE RATE; MICE; MICE, KNOCKOUT; MUSCLE, SKELETAL;

EID: 80455126992     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024564     Document Type: Article

References (52)

1. King H, Aubert RE, Herman WH, (1998) Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21 (9): 1414-31.
2. DeFronzo RA, (1992) Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: A balanced overview. Diabetologia 35 (4): 389-97.
3. Phielix E, Mensink M, (2008) Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol Behav 94 (2): 252-8.
4. Corpeleijn E, Saris WH, Blaak EE, (2009) Metabolic flexibility in the development of insulin resistance and type 2 diabetes: Effects of lifestyle. Obes Rev 10 (2): 178-93.
5. Donovan JM, Von Bergmann K, Setchell KD, Isaacsohn J, Pappu AS, et al. (2005) Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci 50 (7): 1232-8.
6. Davidson MH, (2007) The use of colesevelam hydrochloride in the treatment of dyslipidemia: A review. Expert Opinion on Pharmacotherapy 8 (15): 2569-2578.
7. Insull WJMD, (2006) Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review. Southern Medical Journal 99 (3): 257-273.
8. Bays HE, Goldberg RB, Truitt KE, Jones MR, (2008) Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: Glucose and lipid effects. Arch Intern Med 168 (18): 1975-83.
9. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR, (2008) Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31 (8): 1479-84.
10. Goldberg RB, Fonseca VA, Truitt KE, Jones MR, (2008) Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 168 (14): 1531-40.
11. Onishi T, Sano N, Takikawa H, (2002) Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum. J Gastroenterol Hepatol 17 (6): 697-701.
12. Matsuzaki Y, (2002) Colestimide: The efficacy of a novel anion-exchange resin in cholestatic disorders. J Gastroenterol Hepatol 17 (11): 1133-5.
13. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, et al. (2004) Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 279 (22): 23158-65.
14. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, et al. (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 103 (4): 1006-11.
15. De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, et al. (2003) Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 278 (40): 39124-32.
16. Cariou B, Duran-Sandoval D, Kuipers F, Staels B, (2005) Farnesoid X receptor: A new player in glucose metabolism? Endocrinology 146 (3): 981-3.
17. Duran-Sandoval D, Cariou B, Fruchart JC, Staels B, (2005) Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie 87 (1): 93-8.
18. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, et al. (2004) Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53 (4): 890-8.
19. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, et al. (2005) Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146 (3): 984-91.
20. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, et al. (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81 (5): 687-93.
21. Lefebvre P, Lien F, Cariou B, Kuipers F, Staels B, (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiological Reviews pp. 147.
22. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, et al. (2006) The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281 (16): 11039-49.
23. Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, et al. (2007) Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56 (1): 239-47.
24. Herrema H, Meissner M, van Dijk TH, Brufau G, Boverhof R, et al. (2009) Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptoralpha-controlled metabolic pathways in mice. Hepatology.
25. Bandsma RH, Grefhorst A, van Dijk TH, van der Sluijs FH, Hammer A, et al. (2004) Enhanced glucose cycling and suppressed de novo synthesis of glucose-6-phosphate result in a net unchanged hepatic glucose output in ob/ob mice. Diabetologia 47 (11): 2022-31.
26. van Dijk TH, van der Sluijs FH, Wiegman CH, Baller JF, Gustafson LA, et al. (2001) Acute inhibition of hepatic glucose-6-phosphatase does not affect gluconeogenesis but directs gluconeogenic flux toward glycogen in fasted rats. A pharmacological study with the chlorogenic acid derivative S4048. J Biol Chem 276 (28): 25727-35.
27. van Dijk TH, Boer TS, Havinga R, Stellaard F, Kuipers F, et al. (2003) Quantification of hepatic carbohydrate metabolism in conscious mice using serial blood and urine spots. Anal Biochem 322 (1): 1-13.
28. Lee WN, Byerley LO, Bergner EA, Edmond J, (1991) Mass isotopomer analysis: Theoretical and practical considerations. Biol Mass Spectrom 20 (8): 451-8.
29. Hellerstein MK, Neese RA, (1992) Mass isotopomer distribution analysis: A technique for measuring biosynthesis and turnover of polymers. Am J Physiol 263 (5 Pt 1): E988-1001.
30. Muniyappa R, Lee S, Chen H, Quon MJ, (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294 (1): E15-26.
31. Bligh EG, Dyer WJ, (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 (8): 911-7.
32. Chace DH, DiPerna JC, Mitchell BL, Sgroi B, Hofman LF, et al. (2001) Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clin Chem 47 (7): 1166-82.
33. Gates SC, Sweeley CC, (1978) Quantitative metabolic profiling based on gas chromatography. Clin Chem 24 (10): 1663-73.
34. Plosch T, Kok T, Bloks VW, Smit MJ, Havinga R, et al. (2002) Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J Biol Chem 277 (37): 33870-7.
35. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, et al. (2002) Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 109 (7): 961-971.
36. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115 (6): 1627-35.
37. Chavez JA, Summers SA, (2003) Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Archives of Biochemistry and Biophysics 419 (2): 101-109.
38. Ragheb R, Shanab GML, Medhat AM, Seoudi DM, Adeli K, et al. (2009) Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: Evidence for PKC activation and oxidative stress-activated signaling pathways. Biochemical and Biophysical Research Communications 389 (2): 211-216.
39. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, et al. (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7 (1): 45-56.
40. Shafrir E, (1992) Animal models of non-insulin-dependent diabetes. Diabetes Metab Rev 8 (3): 179-208.
41. Garg A, Grundy SM, (1994) Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 121 (6): 416-22.
42. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL, (2007) Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 29 (1): 74-83.
43. Grefhorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, et al. (2005) Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab 289 (5): E829-838.
44. Boden G, (2003) Effects of free fatty acids (FFA) on glucose metabolism: Significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 111 (3): 121-4.
45. Freeman JS, (2009) Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med 76 (Suppl 5): S12-9.
46. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, et al. (1993) Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns. J Endocrinol 138 (1): 159-166.
47. Rocca AS, LaGreca J, Kalitsky J, Brubaker PL, (2001) Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology 142 (3): 1148-1155.
48. Shang Q, Saumoy M, Holst JJ, Salen G, Xu G, (2010) Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol 298 (3): G419-424.
49. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K, (2011) The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 54 (6): 1263-1272.
50. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149 (12): 6018-27.
51. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58 (1): 250-9.
52. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, et al. (2008) FGF21 is an akt-regulated myokine. FEBS Lett 582 (27): 3805-3810.